UCB : to secure long-term partnership with UNITHER Pharmaceuticals for its Rochester manufacturing facility
Brussels (Belgium), May 29, 2013 - 7 a.m. - UCB has agreed with UNITHER Pharmaceuticals, a leading pharmaceutical manufacturer, that UNITHER will acquire UCB's manufacturing plant in Rochester, New York. The agreement is part of UCB's strategy to optimize its manufacturing network in line with the evolution of its portfolio.
The transaction also includes a six-year supply agreement between UCB and UNITHER and UCB Rochester's approximately 250 employees and 50 temporary staff will all be offered employment opportunities with UNITHER.
The financial details of the agreement were not disclosed. The transaction will have no impact on UCB's financial 2013 outlook.
The transaction is in line with UCB's strategy to increasingly utilize a network of trusted partners for its mass manufacturing activities. By choosing UNITHER as a partner, UCB is confidently transferring its production activities in Rochester to a rapidly-growing manufacturing company that has the highest quality standards and growth ambitions for the site.
For further information UCB
France Nivelle, Global Communications, UCB
T +32.2.559.9178, [email protected]
Laurent Schots, Media Relations, UCB
T +32.2.559.9264, [email protected]
Kristie Madara, US Communications, UCB
T +1.770.970.8726, [email protected]
Antje Witte, Investor Relations, UCB
T +32.2.559.9414, [email protected]
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approx. 9 000 people in about 40 countries, the company generated revenue of EUR 3.4 billion in 2012. UCB is listed on Euronext Brussels (symbol: UCB).
Forward looking statements
This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.
There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.
Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.